Third, stability and BE acceptance: ACTD countries often emphasize climatic zone IV conditions and pragmatic bioequivalence expectations, which require clear crosswalks to US/EU datasets. Keep two principles in mind: (1) do not change the science unless a country explicitly requires new analyses; (2) do change the navigation so reviewers land on proof in one or two clicks. For current reference materials and terminology, regulatory teams should bookmark the International Council for Harmonisation, the U.S. Food & Drug Administration, and the European Medicines Agency.

What follows is a pragmatic, US-first comparison that respects ACTD conventions while keeping the core dossier reusable across multiple authorities. Use it as a planning blueprint for program management (timelines, vendors, budgets) and as a QC checklist for your publishing team.

Module-by-Module Side-by-Side: What Lives Where in ACTD vs CTD (Modules 1–5)

Module 1 — Administrative / Regional. In CTD, Module 1 is wholly regional (forms, cover letters, fee receipts, certifications, labeling artifacts, structured product submissions). ACTD likewise reserves Module 1 for country-specific content, but you should expect: legalized or notarized documents (e.g., POA/authorization letters), wet signatures on declarations, country forms with product particulars, local Good Manufacturing Practice (GMP) certificates, and region-specific labeling leaflets and artwork. Where the US uses SPL/XML for labeling data exchange, many ACTD authorities expect PDF leaflets and national artwork panels (often bilingual). Build a country pack matrix that lists required documents, legalization level, and validity windows so you avoid last-minute scrambles.

Module 2 — Overviews & Summaries. The CTD’s 2.3/2.4/2.5 summaries are globally useful, but ACTD presentation can be more compact and sometimes prescribes different order or headings for Quality vs Clinical/Nonclinical synopses. Keep the same benefit–risk thesis and attribute-level CMC justifications, yet be ready to re-label headings and cut duplicative narrative. Your golden rule: map every key sentence to a Module 3–5 anchor using named destinations so reviewers can verify claims fast, regardless of format.

Module 3 — Quality/CMC. The science is identical (S, P, and where applicable A sections), but ACTD can expect different granularity in certain subsections (e.g., pharmaceutical development narratives and stability particulars). Plan to supply zone-appropriate long-term and accelerated data, container-closure narratives, and attribute-level spec justification tied to clinical relevance, process capability, and method performance. Where a US dossier cites Established Conditions and CPV, your ACTD re-use should still articulate the control strategy thread so assessors see how specs and controls protect patient risk.

Module 4 — Nonclinical. Structure and content transfer well. Ensure GLP/QAU statements are visible, exposure margins are explicitly calculated (AUC/C_max multiples vs clinical exposure), and key figures are legible at laptop zoom. Most ACTD authorities accept the CTD logic if navigation is clean and attestations are present.

Module 5 — Clinical. ICH E3-conformant CSRs, ISS/ISE, and tabulations usually port with minor formatting changes. Expect bioequivalence localization for generics and, for NDAs, occasional emphasis on practical use sections (dose adjustments, special populations). Keep estimand and multiplicity language consistent with CTD; only adapt headings or short bridging paragraphs when national templates ask for it.

Key Concepts and Definitions: CTD, ACTD, eCTD—and What “Granularity” Means in Real Workflows

CTD is a harmonized content framework (Modules 1–5) used by ICH regions and many aligned authorities; eCTD is the electronic exchange format that fixes folder structure, XML backbones, and lifecycle operations. ACTD is the ASEAN packaging of the same scientific content, with its own Module 1 practices and occasional section ordering conventions. Sponsors often confuse format (how files are laid out and named) with content (what the science says). This confusion leads to unnecessary rewrites when a simple remap would suffice.

Granularity is the level at which you split content into leaves (files) and nodes (sections). CTD/eCTD granularity is exacting—CSRs as separate leaves, method reports, validation summaries, etc. ACTD authorities may permit coarser packaging for some sections, especially where paper-era realities persist, but many now expect clear bookmarks and hyperlinks even in PDF bundles. A high-quality ACTD build uses the same leave-nothing-to-chance navigation discipline as eCTD: embedded fonts, searchable text (no image-only scans), deep bookmarks, and links that land on captions, not covers. Treat “granularity” as a review experience question—how quickly can an assessor hit proof—not as a file-count contest.

The persistent myth is that ACTD demands “shorter” dossiers. In reality, most authorities want the same evidence with region-specific wrappers: Module 1 forms, legalized copies, and labeling in local language. Cutting scientific core content is risky; re-framing headings and navigation is not. Establish an internal rule: no content deletions without regulatory citation. When in doubt, keep the CTD evidence and add a short bridging paragraph that points to the appropriate anchors.

Applicable Guidelines and Global Frameworks: Using CTD Artifacts as a Stable Core for ACTD Countries

For terminology and structure, your north stars are the ICH M4 CTD guidance (overall structure) and discipline-specific texts (e.g., Quality, E3 for CSRs). US and EU guidance remains invaluable for constructing the scientific core: FDA expectations on benefit–risk framing, BE design, and labeling clarity; EMA/CHMP conventions for SmPC phrasing and RMP thinking. While ACTD is a regional packaging, many ASEAN national agencies informally anchor to these global texts when assessing adequacy. Hence, a CTD-true core is your best investment for long-term maintainability.

For Quality, retain ICH language around CQAs, CPPs/CMAs, and control strategy, and—where your US dossier references Established Conditions—encapsulate the same maintenance logic in plain words. For Nonclinical, carry forward GLP/QAU attestations and explicit exposure margins so country reviewers can quickly assess safety rationale. For Clinical, keep ICH E3 discipline, clear estimands, multiplicity control, and sensitivity analyses intact; only adjust headings or add short bridges to satisfy country checklists. This approach protects scientific integrity while respecting local presentation rules.

Two practical corollaries follow. First, plan for climatic zone IVb (hot & very humid) stability expectations in many ACTD markets; build your stability plan to cover those conditions early so you are not waiting for time points later. Second, align bioequivalence narratives to country PSG-like expectations where published. Even where ACTD countries differ on protocol specifics, a tight BE rationale (analytes, fed/fasted, sampling windows, stats) translates well across agencies when the intent is clear and data are easy to verify.

Process, Workflow, and Submissions: Converting a US CTD Core to ACTD Without Breaking Traceability

Adopt a “one scientific core, many wrappers” operating model. Start with a frozen CTD base: Module 2 summaries (QOS, 2.4, 2.5), Module 3 with attribute-level spec rationale, Module 4 with GLP/QAU and margins, Module 5 with E3-compliant CSRs/ISS/ISE, and US labeling artifacts. Then build country-pack shells for ACTD Module 1 (forms, letters, legalizations, GMP certificates), labeling leaflets and artwork in local language(s), and any national particulars (reference product declarations, import permissions).

Run a structured conversion workflow:

• Scope & mapping: list each ACTD section and map it to the CTD leaf (file) that will populate it. Record gaps (e.g., translations, notarizations) with owners and due dates.
• Navigation build: stamp named destinations on decisive tables/figures in Modules 3–5; ensure Module 2 claims carry live links that land on captions. Deep bookmarks (H2/H3 + captions) are mandatory—even in ACTD.
• Localization: prepare patient leaflets, HCP texts, and carton/container artwork to country templates; align statements with Module 3 data and Module 2.5 risks; route through bilingual QA.
• Administrative pack: gather legalized/consularized documents; check signature requirements; verify certificate validity windows; insert country forms and declarations.
• QC & packaging: run a link-crawl (on the final zip or PDF package), confirm embedded fonts/searchable text, test bookmarks, and cross-check leaf titles against the country index.

Finally, capture traceability: keep a manifest that shows which CTD file feeds which ACTD node, with hash values for the originals. This protects your chain of custody and simplifies answers to national queries about “what changed” between the US and ACTD filings.

Tools, Templates, and Publishing Pragmatics: File Naming, Granularity, and Reviewer Experience

Templates. Maintain two master sets: (1) a CTD-true Module 2–5 set with boilerplate anchors, caption IDs, and attribute-level patterns (three-legged spec justifications for Quality; GLP/QAU + margins for Nonclinical; estimand and multiplicity blocks for Clinical); and (2) an ACTD Module-1 toolkit with country forms, POA/authorization templates, legalization instructions, and bilingual leaflet shells. Treat artwork as a controlled copy deck with references to Module 3 (storage, strength notation) to prevent drift.

Naming & granularity. Use ASCII-safe, stable file names and a leaf-title catalog that survives lifecycle. Even if a country allows “coarser” bundling, keep caption anchors and bookmarks so assessors can verify claims without scrolling. Where portals request specific filenames, map them to your internal catalog with a simple renaming step at ship time—do not alter the underlying document IDs or anchors.

Navigation & links. A good ACTD set feels like eCTD to a reviewer: click a Module 2 sentence and land on the proof table/figure. Make link insertion a publishing step, not a writer step, and validate with a post-pack link crawl. For countries that still accept paper or hybrid media, print the evidence map (claim → anchor ID) and include it in the administrative cover letter or internal archive to speed query responses.

Readability. Optimize PDFs for laptop reading: embedded fonts, vector figures, and legible axes on plots; avoid image-only scans. For translations, conduct a terminology sweep so key scientific terms maintain one-to-one meanings across languages; maintain a bilingual glossary shared by writing and artwork teams.

Common Challenges and Best Practices: Stability, Labeling, BE, and Administrative “Gotchas”

Stability & climatic zones. Many ACTD markets expect long-term data at zone IV conditions; if your CTD core was built around zone II/III, plan supplementary time points or bracketing/matrixing evidence early. Tie labeled storage statements to Module 3 data—if the box says “protect from moisture,” the dossier must show pack performance and method sensitivity (e.g., CCI). Do not rely on “meets” language without numbers.

Labeling localization. Without SPL XML, ACTD labeling lives as PDFs; that increases the risk of drift between PI text, patient leaflets, and artwork. Control this with a copy deck that cites the exact Module 3/5 anchors for every claim, and run a concordance review before submission (statement ↔ source ID). Keep bilingual leaflets consistent with risk communications in Clinical Overview and, if applicable, risk-minimization statements.

Bioequivalence. For ANDA-like routes, align your BE design with local expectations (analytes, fed/fasted, washout, sampling, stats). Where product-specific guidances exist, cite them; where they don’t, explain how your design meets the intent of equivalence demonstration. If you deviate from a US PSG norm, pre-justify with literature and pilot data; often the rationale matters more than mimicry when local clinics or logistics differ.

Administrative documents. Missed legalizations and expired GMP certificates derail timelines more often than science. Maintain a country validity tracker for each certificate or notarization, and schedule renewals well ahead of slotting. Where blue-ink signatures are requested, plan courier time; some countries reject scanned prints.

Translation QA. Run back-translation or independent proofreading for critical sections (Module 1 declarations, leaflets, key warnings); track changes in a bilingual log so later variations can repeat the process without re-learning terms. When transliteration is required (names, addresses), lock spelling conventions early to avoid inconsistencies across forms, labels, and certificates.

Latest Updates and Strategic Insights: Portfolio Governance, RACI, and “Build Once, Localize Many”

As portfolios globalize, the most successful sponsors treat ACTD vs CTD as a governance problem rather than a writing problem. Establish a RACI (Responsible–Accountable–Consulted–Informed) that names a single owner for (1) the scientific core (CTD-true Modules 2–5), (2) the country pack library (Module 1 forms, legalizations), and (3) labeling/artwork localization. Tie this to release gates: no country pack ships until the link-crawl passes 100%, the bilingual copy deck matches the science anchors, and administrative documents meet validity checks.

Consider a hub-and-spoke build. The hub maintains the CTD core and the evidence map; spokes create ACTD packages per country with a strict “no edits to core” rule, only bridges and wrappers. Spokes request core changes through the hub with regulatory citation. This prevents forking of science across regions and preserves your ability to stage variations consistently (post-approval changes to specs, manufacturing sites, or labeling). When a US supplement (e.g., CBE-30/PAS) is planned, the hub forecasts the downstream ACTD impacts and primes country teams with revised bridges and updated artifacts.

Finally, keep an eye on submission portals and digitization trends. While eCTD is now standard in ICH regions, several ACTD authorities are formalizing electronic gateways with specific filename conventions and PDF checks. Proactively building eCTD-like navigation (anchors, bookmarks, searchable text) makes you ready for those shifts without re-engineering the core. The strategic payoff is a portfolio that moves fast and consistently—one science story, many compliant wrappers, fewer review cycles.